Advertisement

Topics

Motif BioSciences, Inc.???s Second Phase 3 Clinical Trial In ABSSSI Finishes Patient Treatment Phase

20:00 EDT 8 Aug 2017 | BioSpace

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the last patient has completed the treatment phase in REVIVE-2, the second Phase 3 clinical trial investigating...

Original Article: Motif BioSciences, Inc.???s Second Phase 3 Clinical Trial In ABSSSI Finishes Patient Treatment Phase

NEXT ARTICLE

More From BioPortfolio on "Motif BioSciences, Inc.???s Second Phase 3 Clinical Trial In ABSSSI Finishes Patient Treatment Phase"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...